[Immune system and tumors]
- PMID: 28159405
- DOI: 10.1016/j.annpat.2016.12.004
[Immune system and tumors]
Abstract
Despite having been much debated, it is now well established that the immune system plays an essential role in the fight against cancer. In this article, we will highlight the implication of the immune system in the control of tumor growth and describe the major components of the immune system involved in the antitumoral immune response. The immune system, while exerting pressure on tumor cells, also will play a pro-tumoral role by sculpting the immunogenicity of tumors cells as they develop. Finally, we will illustrate the numerous mechanisms of immune suppression that take place within the tumoral microenvironment which allow tumor cells to escape control from the immune system. The increasingly precise knowledge of the brakes to an effective antitumor immune response allows the development of immunotherapy strategies more and more innovating and promising of hope.
Keywords: Cancer; Escape; Immune suppression; Immune surveillance; Immunologie; Immunology; Immunosuppression; Immunosurveillance; Échappement.
Copyright © 2016. Published by Elsevier Masson SAS.
Similar articles
-
Suppressive influences in the immune response to cancer.J Immunother. 2009 Jan;32(1):1-11. doi: 10.1097/CJI.0b013e3181837276. J Immunother. 2009. PMID: 19307988 Review.
-
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?Front Immunol. 2019 Feb 12;10:9. doi: 10.3389/fimmu.2019.00009. eCollection 2019. Front Immunol. 2019. PMID: 30809220 Free PMC article. Review.
-
[Antitumor immunity and cellular cancer therapies].Med Sci (Paris). 2003 Jan;19(1):43-53. doi: 10.1051/medsci/200319143. Med Sci (Paris). 2003. PMID: 12836191 Review. French.
-
Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7. Adv Cancer Res. 2004. PMID: 15530555 Review.
-
Innate immune mediators in cancer: between defense and resistance.Immunol Rev. 2016 Nov;274(1):290-306. doi: 10.1111/imr.12464. Immunol Rev. 2016. PMID: 27782320 Review.
Cited by
-
A Prognostic Signature Based on Immunogenomic Profiling Offers Guidance for Esophageal Squamous Cell Cancer Treatment.Front Oncol. 2021 Feb 24;11:603634. doi: 10.3389/fonc.2021.603634. eCollection 2021. Front Oncol. 2021. PMID: 33718151 Free PMC article.
-
Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction.Cells. 2020 Sep 8;9(9):2053. doi: 10.3390/cells9092053. Cells. 2020. PMID: 32911844 Free PMC article.
-
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy.Front Cell Dev Biol. 2020 Jun 3;8:402. doi: 10.3389/fcell.2020.00402. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32582698 Free PMC article. Review.
-
TLR4 promoter rs1927914 variant contributes to the susceptibility of esophageal squamous cell carcinoma in the Chinese population.PeerJ. 2021 Feb 1;9:e10754. doi: 10.7717/peerj.10754. eCollection 2021. PeerJ. 2021. PMID: 33585082 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources